Dr Hanna drives a discussion regarding breast cancer treatments that have developed resistance to CDK 4/6 inhibitors. Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC: Let’s say a patient wasn’t compliant ...
Regor Pharma, a Shanghai-Boston biotech, sold global rights to Genentech for two early-stage CDK inhibitors aimed at breast cancer. Kailera Therapeutics launched with a four-drug pipeline aimed at the ...
Roche RHHBY announced an asset purchase agreement with clinical-stage biotechnology company Regor Therapeutics. Per the agreement, Roche’s Genentech will acquire Regor’s portfolio of next-generation ...
Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase. Background: PHA-848125 (PHA) is a dual CDK/TRKA oral inhibitor showing ...
(RTTNews) - Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will acquire a portfolio of next-generation CDK inhibitors ...
CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...
Scientists at Foshan Ionova Biotherapeutics Co. Ltd., Guangdong Touchstone Translational Research Institute Co. Ltd. and Shenzhen Ionova Life Science Co. Ltd. have described tricyclic compounds acting ...
OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced it has reached an agreement to acquire GT Apeiron’s share of its oral CDK7 inhibitor programme, gaining full control of ...
Roche’s Genentech subsidiary has agreed to pay the biotechnology firm Regor Pharmaceuticals $850 million, plus possible milestone payments, for a portfolio of CDK inhibitors for treating breast cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback